中金将IMAB目标价提高至29.39美元：在研产品临床进展值得期待

2020-06-03

2020年5月30日，中金发布报告将天境生物（NASDAQ：IMAB）目标价提升至29.39美元每ADS。中金在报告中分析，因疫情期间，公司临床进展稳步推进，暂未受到较大负面影响，因此预计后续临床试验开展的节奏或相对可控；同时，考虑到公司在研产品进展陆续取得阶段性突破，故上调公司目标价62.5%至29.39美元每ADS，维持跑赢行业评级。$天境生物(IMAB)$

2020年的疫情启示录

相信大家在这段居家的日子总有一些感悟，一起来谈谈你的“2020年疫情启示录”，参加征文活动，赢惊喜～

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

精彩评论

昨夜梦见你
2020-06-09
昨夜梦见你
到了我就跑

发表看法

{"i18n":{"language":"zh_CN"},"detailType":1,"isChannel":false,"data":{"magic":2,"id":958355894,"tweetId":"958355894","gmtCreate":1591181932818,"gmtModify":1704194673724,"author":{"id":3546318476404641,"authorId":3546318476404641,"authorIdStr":"3546318476404641","name":"天境生物","avatar":"https://static.tigerbbs.com/6c790321aa0e34c85e2c789416a37e11","vip":5,"userType":5,"introduction":"处于临床阶段的创新生物药公司","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":2536,"starInvestorFlag":false},"themes":[{"themeId":"e8f3a12b2b8d429698bb57946d462220","categoryId":"d3c66e9d6c224ba082ca76ee654847ca","name":"2020年的疫情启示录","type":0,"rnLink":"https://laohu8.com/RN?name=RNTheme&page=/theme/detail&rndata={\"themeId\":e8f3a12b2b8d429698bb57946d462220}&rnconfig={\"headerBarHidden\": true}","description":"相信大家在这段居家的日子总有一些感悟，一起来谈谈你的“2020年疫情启示录”，参加征文活动，赢惊喜～\n","image":"https://static.tigerbbs.com/c163dab03a2862770451a27a4e70b721"}],"images":[],"coverImages":[],"title":"中金将IMAB目标价提高至29.39美元：在研产品临床进展值得期待","extraTitle":"","html":"<html><head></head><body><p>2020年5月30日，中金发布报告将天境生物（NASDAQ：IMAB）目标价提升至29.39美元每ADS。中金在报告中分析，因疫情期间，公司临床进展稳步推进，暂未受到较大负面影响，因此预计后续临床试验开展的节奏或相对可控；同时，考虑到公司在研产品进展陆续取得阶段性突破，故上调公司目标价62.5%至29.39美元每ADS，维持跑赢行业评级。<a target=\"_blank\" href=\"https://laohu8.com/S/IMAB\">$天境生物(IMAB)$</a></p></body></html>","htmlText":"<html><head></head><body><p>2020年5月30日，中金发布报告将天境生物（NASDAQ：IMAB）目标价提升至29.39美元每ADS。中金在报告中分析，因疫情期间，公司临床进展稳步推进，暂未受到较大负面影响，因此预计后续临床试验开展的节奏或相对可控；同时，考虑到公司在研产品进展陆续取得阶段性突破，故上调公司目标价62.5%至29.39美元每ADS，维持跑赢行业评级。<a target=\"_blank\" href=\"https://laohu8.com/S/IMAB\">$天境生物(IMAB)$</a></p></body></html>","text":"2020年5月30日，中金发布报告将天境生物（NASDAQ：IMAB）目标价提升至29.39美元每ADS。中金在报告中分析，因疫情期间，公司临床进展稳步推进，暂未受到较大负面影响，因此预计后续临床试验开展的节奏或相对可控；同时，考虑到公司在研产品进展陆续取得阶段性突破，故上调公司目标价62.5%至29.39美元每ADS，维持跑赢行业评级。$天境生物(IMAB)$","highlighted":1,"essential":1,"paper":2,"likeSize":2,"commentSize":1,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/958355894","repostId":0,"isVote":1,"tweetType":1,"viewCount":2805,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["IMAB"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":304,"xxTargetLangEnum":"ZH_CN"},"commentList":[{"id":2522408,"gmtCreate":1591710860570,"gmtModify":1591710860570,"authorId":3545737789066182,"author":{"id":3545737789066182,"authorId":3545737789066182,"name":"昨夜梦见你","avatar":"https://static.tigerbbs.com/946db8818ec39ea6c860bbfe06e8677b","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":958355894,"type":1,"supId":0,"prevId":0,"content":"到了我就跑","text":"到了我就跑","html":"到了我就跑","likeSize":0,"commentSize":0,"subComments":[],"verified":10,"allocateAmount":0,"commentType":"valid","coins":0,"score":0}],"isCommentEnd":false,"isTiger":false,"isWeiXinMini":false,"url":"/m/post/958355894"}